Application of 99mTechnetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients. A first-in-man study.

Nuclear Medicine and Biology

Volumn 40, Issue 7, 2013, Pages 933-938

  Ananias, Hildo J K ^a   Yu, Zilin ^a   Hoving, Hilde D ^a   Rosati, Stefano ^a   Dierckx, Rudi A ^a   Wang, Fan ^b   Yan, Yongjun ^c   Chen, Xiaoyuan ^c   Pruim, Jan ^a,d   Lub de Hooge, Marjolijn N ^a   Helfrich, Wijnand ^a   Elsinga, Philip H ^a   de Jong, Igle J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b PEKING UNIVERSITY   (China)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^d STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Bombesin; First in man; GRPR; Prostate cancer; SPECT CT

Indexed keywords

GASTRIN RELEASING PEPTIDE RECEPTOR; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 6 HYDRAZINONICOTINIC ACID(TRICINE TRISODIUM TRIPHENYLPHOSPHINE 3,3',3 TRISULFONATE)AMINOCAPROIC ACID BOMBESIN[7-14] TC 99M; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG STABILITY; EXTERNAL BEAM RADIOTHERAPY; FEASIBILITY STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; PATIENT SAFETY; PILOT STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BOMBESIN; FIRST-IN-MAN; GRPR; PROSTATE CANCER; SPECT/CT;

AGED; AMINOCAPROIC ACID; DRUG STABILITY; FEASIBILITY STUDIES; GLYCINE; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PEPTIDE FRAGMENTS; PILOT PROJECTS; PROSTATIC NEOPLASMS; QUALITY CONTROL; RECEPTORS, BOMBESIN; SULFONIC ACIDS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84883560208     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.05.009     Document Type: Article

References (26)

1. Center M.M., Jemal A., Lortet-Tieulent J., Ward E., Ferlay J., Brawley O., et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012, 61(6):1079-1092.
2. Arora R., Koch M.O., Eble J.N., Ulbright T.M., Li L., Cheng L. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004, 100(11):2362-2366.
3. Eichler K., Hempel S., Wilby J., Myers L., Bachmann L.M., Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006, 175(5):1605-1612.
4. Chang J.J., Shinohara K., Bhargava V., Presti J.C. Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol 1998, 160(6 Pt 1):2111-2114.
5. Presti J.C., Chang J.J., Bhargava V., Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000, 163(1):163-166. [discussion 166-7].
6. Levy D.A., Jones J.S. Management of rising prostate-specific antigen after a negative biopsy. Curr Urol Rep 2011.
7. Resnick M.J., Lee D.J., Magerfleisch L., Vanarsdalen K.N., Tomaszewski J.E., Wein A.J., et al. Repeat prostate biopsy and the incremental risk of clinically insignificant prostate cancer. Urology 2011, 77(3):548-552.
8. Mariani G., Bruselli L., Kuwert T., Kim E.E., Flotats A., Israel O., et al. A review on the clinical uses of SPECT/CT. Eur J Nucl Med Mol Imaging 2010, 37(10):1959-1985.
9. Ambrosini V., Fani M., Fanti S., Forrer F., Maecke H.R. Radiopeptide imaging and therapy in Europe. J Nucl Med 2011, 52(Suppl. 2):42S-55S.
10. De Jong I.J., De Haan T.D., Wiegman E.M., Van Den Bergh A.C., Pruim J., Breeuwsma A.J. PET/CT and radiotherapy in prostate cancer. Q J Nucl Med Mol Imaging 2010, 54(5):543-552.
11. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med 2011, 52(1):81-89.
12. Ananias H.J., van den Heuvel M.C., Helfrich W., de Jong I.J. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 2009, 69(10):1101-1108.
13. Beer M., Montani M., Gerhardt J., Wild P.J., Hany T.F., Hermanns T., et al. Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate 2012, 72(3):318-325.
14. Aprikian A.G., Cordon-Cardo C., Fair W.R., Reuter V.E. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993, 71(12):3952-3965.
15. Cutz E., Chan W., Track N.S. Bombesin, calcitonin and leu-enkephalin immunoreactivity in endocrine cells of human lung. Experientia 1981, 37(7):765-767.
16. Price J., Penman E., Wass J.A., Rees L.H. Bombesin-like immunoreactivity in human gastrointestinal tract. Regul Pept 1984, 9(1-2):1-10.
17. Spindel E.R., Chin W.W., Price J., Rees L.H., Besser G.M., Habener J.F. Cloning and characterization of cDNAs encoding human gastrin-releasing peptide. Proc Natl Acad Sci U S A 1984, 81(18):5699-5703.
18. Schroeder R.P., van Weerden W.M., Bangma C., Krenning E.P., de Jong M. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods 2009, 48(2):200-204.
19. Ananias H.J., de Jong I.J., Dierckx R.A., van de Wiele C., Helfrich W., Elsinga P.H. Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals. Curr Pharm Des 2008, 14(28):3033-3047.
20. Ananias H.J., Yu Z., Dierckx R.A., van der Wiele C., Helfrich W., Wang F., et al. (99m)technetium-HYNIC(tricine/TPPTS)-Aca-bombesin(7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model. Mol Pharm 2011, 8(4):1165-1173.
21. Linder K.E., Metcalfe E., Arunachalam T., Chen J., Eaton S.M., Feng W., et al. In vitro and in vivo metabolism of Lu-AMBA, a GRP-receptor binding compound, and the synthesis and characterization of its metabolites. Bioconjug Chem 2009, 20(6):1171-1178.
22. Konkoy C.S., Davis T.P. Ectoenzymes as sites of peptide regulation. Trends Pharmacol Sci 1996, 17(8):288-294.
23. Ocak M., Helbok A., von Guggenberg E., Ozsoy Y., Kabasakal L., Kremser L., et al. Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative. Nucl Med Biol 2011, 38(2):171-179.
24. Ocak M., Helbok A., Rangger C., Peitl P.K., Nock B.A., Morelli G., et al. Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. Eur J Nucl Med Mol Imaging 2011, 38(8):1426-1435.
25. Schroeder R.P., Muller C., Reneman S., Melis M.L., Breeman W.A., de Blois E., et al. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging 2010, 37(7):1386-1396.
26. Scopinaro F., De Vincentis G., Varvarigou A.D., Laurenti C., Iori F., Remediani S., et al. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging 2003, 30(10):1378-1382.